Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation.
BACKGROUND
Treg based immunotherapy is of great interest to facilitate tolerance in autoimmunity and transplantation. For clinical trials, it is essential to have a clinical grade Treg isolation protocol in accordance with Good Manufacturing Practice (GMP) guidelines. To obtain sufficient Treg for immunotherapy, subsequent ex vivo expansion might be needed.


RESULTS
Treg were isolated from leukapheresis products by CliniMACS based GMP isolation strategies, using anti-CD25, anti-CD8 and anti-CD19 coated microbeads. CliniMACS isolation procedures led to 40-60% pure CD4(pos)CD25(high)FoxP3(pos) Treg populations that were anergic and had moderate suppressive activity. Such CliniMACS isolated Treg populations could be expanded with maintenance of suppressive function. Alloantigen stimulated expansion caused an enrichment of alloantigen-specific Treg. Depletion of unwanted CD19(pos) cells during CliniMACS Treg isolation proved necessary to prevent B-cell outgrowth during expansion. CD4(pos)CD127(pos) conventional T cells were the major contaminating cell type in CliniMACS isolated Treg populations. Depletion of CD127(pos) cells improved the purity of CD4(pos)CD25(high)FoxP3(pos) Treg in CliniMACS isolated cell populations to approximately 90%. Expanded CD127(neg) CliniMACS isolated Treg populations showed very potent suppressive capacity and high FoxP3 expression. Furthermore, our data show that cryopreservation of CliniMACS isolated Treg is feasible, but that activation after thawing is necessary to restore suppressive potential.


CONCLUSIONS
The feasibility of Treg based therapy is widely accepted, provided that tailor-made clinical grade procedures for isolation and ex vivo cell handling are available. We here provide further support for this approach by showing that a high Treg purity can be reached, and that isolated cells can be cryopreserved and expanded successfully.
Peters
Jorieke H
JH
Department of Bloodtransfusion and Transplantation Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Preijers
Frank W
FW
Woestenenk
Rob
R
Hilbrands
Luuk B
LB
Koenen
Hans J P M
HJ
Joosten
Irma
I
D018941:Antigens, CD19 / Q000096:biosynthesis; D001402:B-Lymphocytes / Q000276:immunology; D016827:CD8 Antigens / Q000096:biosynthesis; D019411:Clinical Laboratory Techniques / Q000592:standards*; D018920:Coculture Techniques; D015925:Cryopreservation / Q000379:methods* / Q000592:standards; D051858:Forkhead Transcription Factors / Q000096:biosynthesis; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy / Q000295:instrumentation* / Q000379:methods; D053645:Interleukin-2 Receptor alpha Subunit / Q000096:biosynthesis; D053699:Interleukin-7 Receptor alpha Subunit / Q000378:metabolism*; D007519:Isoantigens / Q000737:chemistry; D007937:Leukapheresis; D050378:T-Lymphocytes, Regulatory / Q000378:metabolism*
D018941:Antigens, CD19; D016827:CD8 Antigens; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D053645:Interleukin-2 Receptor alpha Subunit; D053699:Interleukin-7 Receptor alpha Subunit; D007519:Isoantigens
J Immunol. 2002 Nov 1;169(9):4712-6
12391178
Blood. 1999 Oct 1;94(7):2208-16
10498590
J Exp Med. 2004 Jun 7;199(11):1467-77
15184500
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2758-63
16473944
J Immunol. 2005 Mar 15;174(6):3290-7
15749860
Clin Immunol. 2005 Apr;115(1):3-9
15870014
J Exp Med. 2002 Aug 5;196(3):389-99
12163567
Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67
15979320
J Immunol. 2003 Apr 15;170(8):3939-43
12682220
J Immunol. 2005 Jun 15;174(12):7573-83
15944257
Biol Blood Marrow Transplant. 2006 Mar;12(3):267-74
16503495
J Immunol Methods. 2006 Jul 31;314(1-2):103-13
16860335
Blood. 2004 Jun 1;103(11):4216-21
14976053
J Immunother. 2006 May-Jun;29(3):336-49
16699377
J Immunol. 2005 Sep 1;175(5):3053-9
16116193
Nat Med. 2003 Sep;9(9):1144-50
12925844
J Exp Med. 2006 Jul 10;203(7):1693-700
16818676
J Exp Med. 2004 Jun 7;199(11):1455-65
15184499
Bone Marrow Transplant. 1999 Feb;23(3):251-8
10084256
PLoS One. 2008 May 21;3(5):e2233
18493605
Biol Blood Marrow Transplant. 2003 Apr;9(4):243-56
12720217
J Immunol Methods. 2006 Aug 31;315(1-2):27-36
16887141
Blood. 2007 Jan 15;109(2):827-35
17003369
Blood. 2004 Aug 1;104(3):895-903
15090447
J Immunol. 2003 Dec 15;171(12):6431-41
14662842
J Clin Invest. 2003 Dec;112(11):1688-96
14660744
Nat Rev Immunol. 2007 Aug;7(8):585-98
17653126
J Exp Med. 2006 Jul 10;203(7):1701-11
16818678